MetaboScape 2.0

Aug 22, 2016

Bruker has released MetaboScape 2.0, the latest version of its solution for metabolomics research and routine analysis. The solution, which links LC-QTOF-MS/MS data from Bruker's Impact II mass spectrometers to metabolic pathways, includes tools for identifying and annotating known and unknown compounds as well as statistical tools for identifying relevant information in metabolomics datasets. 

More Like This

Dec 14, 2018

Enpicom Expanded ImmunoGenomics Platform

Enpicom has finalized and launched an expanded version of its ImmunoGenomix platform, which it said will support discovery and development of novel immunotherapies, patient stratification for, and treatment monitoring of immunotherapies. The platform now also accepts B cell receptor as well as T cell receptor sequencing data. 

Dec 14, 2018

Microbiologics Group A Streptococcus and Respiratory Control Panels

Microbiologics has launched its Group A Streptococcus and Respiratory Panels, as well as test meothodsto help clinical laboratories deliver accurate results during cold and flue season. The panels include features suc has multiplexed pellets, swabs that mimic patient sample processing, and room temperature storage. 

Dec 12, 2018

Expedeon MagniPhi & QualiPhi DNA Polymerases

Expedeon has launched two high-fidelity polymerases, MagniPhi DNA Polymerase and QualiPhi DNA Polymerase. Expedeon offers the products in both 25- and 100-reaction kits, which contain DNA polymerases and their associated reaction buffers. The firm said MagniPhi — a wild-type form of the Phi29 DNA polymerase — is ideal for isothermal DNA amplification. According to Expedeon, MagniPhi's fidelity of synthesis produces up to 100 times fewer errors than Taq polymerase, while the amplification reaction yields more whole-genome amplification compared to normal PCR-based WGA techniques.

Expedeon's QualiPhi — a chimeric form of the Phi29 DNA Polymerase — has been engineered for enhanced sensitivity and efficiency while preserving the high processivity of the wild type Phi29. According to the firm, the polymerase's higher sensitivity allows improved amplification of DNA from low to high input concentrations and higher yields than the wild-type polymerase.

Dec 11, 2018

Proteona ESCAPE RNA Sequencing

Proteona, a spinout from the National University of Singapore and A*STAR, has launched Enhanced Single-Cell Analysis with Protein Expression (ESCAPE) RNA sequencing as a service and early access kit. ESCAPE RNA-seq measures both gene expression and proteins from the same single cells. Proteona provides the antibodies and reagents for making the protein expression sequencing libraries and 10x Genomics' platform can then be used to make the single-cell RNA sequencing libraries.

Dec 11, 2018

Indigo Biosciences Gene Expression Assay Kit

Indigo has launched a gene expression assay kit featuring optimized "Upcyte" hepatocytes, which are human donor-derived liver cells established by Upcyte Technologies. The kit provides optimized reagents for culturing and treatment of Upcyte hepatocytes to examine drug-induced changes in the expression of seven clinically relevant cytochrome P450 enzymes. According to the firm, the hepatocytes combine the advantages of primary hepatocytes with the added practical advantage of having access to the same donor cells for use in iterative, large-scale testing over extended periods.

Dec 11, 2018

ZeptoMetrix Pneumonia Verification Panels

ZeptoMetrix has released two pneumonia verification panels for molecular quality control, the NATrol Pneumonia Panel-Atypical Bacteria & Viruses and NATrol Pneumonia Panel-Quantifiable Bacteria. The Buffalo, New York-based company designs, develops, and markets solutions for the infectious disease diagnostics space. 

Dec 11, 2018

Cellecta DriverMap RNA-Seq Panels, Analysis Software

Cellecta has launched five DriverMap Predesigned RNA-Seq panels, including the Human Cell Marker Panel, Human Hallmark Signatures Panel, Human LINCSx Panel, Human Pan-Cancer Pathway Panel, and the Human Transcription Factor Signature Panel. Each panel measures expression levels of over 1,200 curated essential genes selected from publications, open access databases, and other resources. The panels use the same multiplex RT-PCR followed by next-generation sequencing approach as the firm's DriverMap Expression Profiling assay, which measures expression levels of all protein-coding human genes.

The kits include a complete set of gene-specific and PCR-NGS primers, buffers, spiked-in EERC and positive control RNAs, as well as all necessary reagents required to profile 96 samples and prepare them for digital expression profiling on a Illumina sequencing platform also come with genome alignment software that provides differential expression data in an excel spreadsheet format. 

Dec 07, 2018

Allele Biotech Stem Cells

Allele Biotech has produced its initial batch of six induced pluripotent stem cell (iPSC) lines. The firm's iPSCs were created using its mRNA technologies, with full cGMP monitoring and documentation starting from donor consent, screening, and tissue biopsy.  In addition to iPSC generation and differentiation, customers can use Allele's mRNA platform to engineer human iPSC s in a one-time genetic modification event to create a clonal iPSC line that can be developed into a master cell bank.

Dec 05, 2018

Thermo Fisher Scientific Invitrogen Collibri Stranded RNA Library Prep Kits for Illumina Systems

Thermo Fisher Scientific has launched a new line of Invitrogen next-generation sequencing library preparation kits that are compatible with Illumina sequencing systems. The Invitrogen Collibri Stranded RNA Library Prep Kits for Illumina Systems come in two versions, one for whole transcriptome sequencing that includes ribosomal depletion and one for mRNA sequencing that does not. The kits are currently available outside of the Americas.

Dec 03, 2018

Insight Genetics Insight TNBCtype

Insight Genetics has launched Insight TNBCtype, a new test for categorizing triple negative breast cancers (TNBC) into distinct molecular subtypes. Offered through its CLIA-certified and CAP-accredited lab, Insight Molecular Labs, the new test is intended to help advance prospective clinical trials of targeted therapies for TNBC patients.

TNBC, which represents up to 15-20 percent of all breast cancers, is an aggressive disease, characterized by an absence of ER, PR, and HER2 expression. Insight TNBCtype is based on a proprietary algorithm that uses gene expression data from next-generation sequencing to generate five molecular subtypes (BL1, BL2, LAR, MSL and M), as well as a complementary immunomodulatory (IM) classifier that may help predict response to immuno-oncology therapies. 

Nov 30, 2018

Qiagen QiaScreen HPV PCR Test

Qiagen announced the European launch of its QiaScreen HPV PCR test, a CE-IVD marked molecular diagnostic assay for 15 recognized high-risk genotypes of human papillomavirus associated with cervical cancer. The assay is designed to detect a range of DNA targets within the E7 region of the HPV virus, providing the flexibility of PCR without the risk of false positives due to L1 deletion, Qiagen said. The clinical performance of the assay was tested using nearly 1,600 samples from the Valgent-3 panel, and was reported to have a clinical sensitivity and specificity to CIN3+ of 97.3 percent and 89.0 percent, respectively. The assay is designed for use on either clinician-collected or self-collected specimens, and it has been validated on Qiagen's Rotor-Gene Q MDx system. Qiagen also intends to offer a version of the test on the NeuMoDx 96 and 288 molecular systems in the future for customers desiring higher-volume testing and full integration.

Nov 29, 2018

Qiagen CLC Genomics Workbench 12; QCI Interpret Workflow; QiaAct Myeloid Panel

Qiagen has launched the new CLC Genomics Workbench 12 sequencing analysis software, which incorporates features of two previous Qiagen products: the CLC Biomedical Genomics Workbench and CLC Genomics Workbench. The new product features a streamlined and simple interface designed for scientists with any bioinformatics skill level, Qiagen said. The data footprint is reduced by more than half compared to previous products. In addition, an in-depth reference tool suite allows users to quickly start work on many commonly studied species and genomic panels, the company noted. Current users of the CLC Biomedical Genomics Workbench can choose to upgrade to the new product free of charge.

The firm also launched a new workflow for the Qiagen Clinical Insight Interpret web-based clinical decision support platform for hematological malignancies. Qiagen designed the workflow to work with the heterogeneous nature of and provide actionable information for the sub-classification and prognostic assessment of these malignancies, including leukemia, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, and multiple myeloma. QCI Interpret draws upon the Qiagen Knowledge Base to evaluate genomic variants in the context of published biomedical literature, professional association guidelines (AMP/ASCO/CAP and ACMG/AMP), publicly and privately available databases, drug labels, and clinical trials.

Lastly, Qiagen launched the QiaAct Myeloid UMI Panel for the GeneReader NGS system. The panel covers 25 highly relevant genes and their variants, including single nucleotide variants and insertions/deletions of known significance to clonal myeloid malignancy. The gene targets have been thoroughly selected for their occurrence and relevance in myeloid malignancies as stated by international references and organizations, including the 2016 WHO classification categories, National Comprehensive Cancer Network, European LeukemiaNet, MPN&MPNr-EuroNet, and the European Society for Medical Oncology. Among the genes targeted are JAK2, CALR, IDH1/2, FLT3, KIT, SRSF2, and TP53.

Nov 28, 2018

Swift Biosciences Normalase Kit

Swift Biosciences has launched the Normalase Kit, an enzymatic library normalization kit for next-generation sequencing library preparation. According to the company, the kit reduces sequencing read depth variation within a pool down to a coefficient of variation less than 10 percent. The kit is compatible with library prep workflows from Swift, Illumina, and Roche/Kapa.

Nov 27, 2018

SoftGenetics MaSTR Probabilistic Mixture Analysis Software

SoftGenetics has released a new probabalistic mixture analysis software product called MaSTR. Designed according to probabalistic guidelines set by the Organization of Scientific Area Committees for Forensic Science and the Scientific Working Group on DNA Analysis Methods, MaSTR is meant to provide transparency to help forensic professionals better describe DNA findings in courtrooms. State College, Pennsylvania-based SoftGenetics said that it is making the MaSTR analysis code available to users on a confidential basis only.

Nov 26, 2018

OncoDNA OncoDeep

OncoDNA has released an updated version of its OncoDeep solid tumor analysis tool. The firm's OncoDeep assay sequences a total of 313 genes, compared to 75 for the original product. The panel includes more genes involved in immunotherapy selection and homologous recombination deficiency for PARP inhibitors. OncoDNA said that the next-generation sequencing panel has a broader detection of fusions with new probes, as well as a broader MSI coverage to increase the accuracy of the firm's algorithm.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.